Researchers at UCL and UCLH have successfully completed the first trial of a therapy designed to restore hearing loss. The REGAIN trial, the results of which were published in Nature Communications, was the first study of a treatment aimed at restoring lost hearing, focusing on a drug with the technical name gamma-secretase inhibitor LY3056480.
The researchers found that while the therapy did not restore hearing across the group of adults with mild to moderate hearing loss, a deeper analysis of the data showed changes in various hearing tests in some patients, suggesting the drug has some activity in the inner ear.
These so-called efficacy signals call for further development of LY3056480—using the learnings from this trial.
Leave a reply